Table 4.

Chronic tubulointerstitial changes associated with macrovacuoles on biopsy at 3 mo among IVIg-treated patientsa

ParametersMacrovacuoles at 3 moP
Yes (n = 17)No (n = 10)
Banff scores on pretransplantation biopsy
    interstitial fibrosis (mean ± SD)0.13 ± 0.350.20 ± 0.42NS
    tubular atrophy (mean ± SD)0.12 ± 0.330.10 ± 0.32NS
    IF/TA (n [%])1 (5.9)1 (10.0)NS
    IF/TA score (mean ± SD)0.06 ± 0.240.10 ± 0.32NS
Banff scores at 3 mo
    glomerulitis (mean ± SD)0.00 ± 0.000.00 ± 0.00NS
    interstitial infiltrate (mean ± SD)0.41 ± 0.510.00 ± 0.00NS
    tubulitis (mean ± SD)0.41 ± 0.790.30 ± 0.48NS
    vasculitis (mean ± SD)0.41 ± 0.790.30 ± 0.48NS
    allograft glomerulopathy (mean ± SD)0.00 ± 0.000.00 ± 0.00NS
    interstitial fibrosis (mean ± SD)1.65 ± 0.930.60 ± 1.07<0.010
    change in interstitial fibrosis (day 0 to 3 mo; mean ± SD)1.53 ± 0.940.40 ± 1.17<0.010
    tubular atrophy (mean ± SD)1.41 ± 1.000.60 ± 1.07<0.010
    change in tubular atrophy (day 0 to 3 mo; mean ± SD)1.29 ± 0.850.50 ± 1.18<0.040
    IF/TA lesions (n [%])14 (82.4)3 (30.0)<0.007
    IF/TA mean score (mean ± SD)1.40 ± 1.000.60 ± 1.10<0.030
    change in IF/TA score (day 0 to 3 mo; mean ± SD)1.40 ± 0.900.50 ± 1.20<0.030
  • a IT/TA, interstitial fibrosis/tubular atrophy.